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Abstract
Background: In estrogen responsive MCF-7 cells, estradiol (E2) binding to ERa leads to transcriptional regulation of
genes involved in the control of cell proliferation and survival. MicroRNAs (miRNAs) have emerged as key post-
transcriptional regulators of gene expression. The aim of this study was to explore whether miRNAs were involved
in hormonally regulated expression of estrogen responsive genes.
Methods: Western blot and QPCR were used to determine the expression of estrogen responsive genes and
miRNAs respectively. Target gene expression regulated by miRNAs was validated by luciferase reporter assays and
transfection of miRNA mimics or inhibitors. Cell proliferation was evaluated by MTS assay.
Results: E2 significantly induced bcl-2, cyclin D1 and survivin expression by suppressing the levels of a panel of
miRNAs (miR-16, miR-143, miR-203) in MCF-7 cells. MiRNA transfection and luciferase assay confirmed that bcl-2
was regulated by miR-16 and miR-143, cyclinD1 was modulated by miR-16. Importantly, survivin was found to be
targeted by miR-16, miR-143, miR-203. The regulatory effect of E2 can be either abrogated by anti-estrogen ICI 182,
780 and raloxifene pretreatment, or impaired by ERa siRNA, indicating the regulation is dependent on ERa. In
order to investigate the functional significance of these miRNAs in estrogen responsive cells, miRNAs mimics were
transfected into MCF-7 cells. It revealed that overexpression of these miRNAs significantly inhibited E2-induced cell
proliferation. Further study of the expression of the miRNAs indicated that miR-16, miR-143 and miR-203 were
highly expressed in triple positive breast cancer tissues, suggesting a potential tumor suppressing effect of these
miRNAs in ER positive breast cancer.
Conclusions: These results demonstrate that E2 induces bcl-2, cyclin D1 and survivin by orchestrating the
coordinate downregulation of a panel of miRNAs. In turn, the miRNAs manifest growth suppressive effects and
control cell proliferation in response to E2. This sheds a new insight into the integral post-transcriptional regulation
of cell proliferation and survival genes by miRNAs, a potential therapeutic option for breast cancer.
Background
17-b-estradiol (E2) regulates genes directly by binding to
estrogen receptors (ERs) that are ligand-activated tran-
scription factors and indirectly by activating plasma
membrane-associated ERs which, in turn, activates intra-
cellular signaling cascades leading to altered gene
expression [1]. Therefore, ERs may participate in both
the genomic (transcriptional) and non-genomic actions
of E2 [2]. E2-liganded ERs interacts directly with a
specific DNA sequence called the estrogen response ele-
ment (ERE = 5’-AGGTCAnnnTGACCT-3’) located in
the promoter region of target genes [3]. DNA bound
ERs then recruits transcriptional coregulators or inter-
acts with other transcription factors, such as AP-1[4]
and Sp-1 [5] to indirectly modulate target gene
transcription.
To date, two isoforms of the ERs (a and b) have been
identified which are able to bind to DNA as homo- or
heterodimers. However, it has been shown that, in
MCF-7 cells, ERa represents the predominant form,
while ERb is barely detectable [6]. Most studies so far
have focused on E2-ERa mediated transcriptional
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regulation of genes involved in the control of cell prolif-
eration and survival. It has been reported that E2 up-
regulates the bcl-2 mRNA level in MCF-7 cells via two
EREs located within the coding region [7]. The expres-
sion of cyclin D1, a gene involved in G1 phase cell cycle
progression, is induced by E2 in human breast cancer
cells. Further studies have identified multiple enhancer
elements involved in this regulation [8-11]. E2 also
induces survivin upregulation as shown by a gene
expression profiling analysis [12]. In hormone-respon-
sive human breast cancer cells, ligand-activated ERa
regulates target gene transcription by binding to their
DNA response elements (EREs) or by tethering to other
trans-acting factors [13,14]. However, the effect of E2 on
gene expression at the post-transcriptional level still
needs further investigation.
MicroRNAs (miRNAs) are a class of evolutionarily
conserved small, non-coding RNAs that control gene
expression at the post-transcriptional level [15]. They
regulate gene expression by base pairing to the 3’UTR
of target mRNA, resulting in direct cleavage and/or
translation inhibition of the target mRNA [16,17]. Sev-
eral studies on miRNA array analysis in MCF-7 cells
have demonstrated that E2 regulates a variety of miR-
NAs. E2 upregulates 21 miRNAs and downregulated 7
miRNAs in MCF-7 vector control stable cells treated
with E2 for 4 h [18]. E2 downregulates the expression of
mature miRNAs and pre-miRNAs (miR-195, miR-125a,
miR-143, miR-145, miR-16, miR-190), but not pri-miR-
NAs in both mice and cells [19]. Maillot et al. [20] have
shown the expression of a broad set of miRNAs (miR-
181a, miR-21, miR-26a, miR-200c, miR-27b, miR-23b)
decreases following E2 treatment in an ER-dependent
manner. Based on previous microRNA expression profil-
ings, we demonstrated that miR-16, miR-143 and miR-
203 were potentially suppressed in response to E2 treat-
ment in MCF-7 cells by QPCR quantification. Recently,
estradiol-regulated miRNAs have been reported to con-
trol estrogen response and cell growth in breast cancer
cells [18,20]. However, whether these estradiol-repressi-
ble miRNAs coordinately control cell proliferation and
survival by targeting bcl-2, cyclin D1 and survivin at the
post-transcriptional level in breast cancer cells is not
fully investigated.
In the present study, we demonstrated that E2 signifi-
cantly induced bcl-2, cyclin D1 and survivin expression
by suppressing the expression of a set of miRNAs in
ERa dependent manner in MCF-7 cells. The downregu-
lated miRNAs exhibited the growth suppressive effect in
response to E2 and were highly expressed in triple posi-
tive breast cancer tissues. The study revealed the post-
transcriptional regulation of estradiol-induced cell prolif-
eration and survival genes by coordinately suppressing a
panel of miRNAs, which may serve as therapeutic
options in breast cancer treatment.
Methods
Cells and treatment
17b-estradiol, raloxifene, fulvestrant (ICI 182, 780) were
purchased from Sigma (Sigma, St. Louis, MO). The
breast cancer cells MCF-7, MDA-MB-231 were obtained
from the American Type Culture Collection (ATCC,
Rockville, MD) and were maintained at 37°C under 5%
CO2. MCF-7 cells were maintained in IMEM medium
supplemented with 10% fetal bovine serum (FBS) and
0.01 mg/ml bovine insulin (Invitrogen, Carlsbad, CA).
MDA-MB-231 were maintained in DMEM medium with
10% FBS. Prior to ligand treatment, cells were incubated
with phenol red-free IMEM supplemented with 5% char-
coal stripped FBS for 48 h (serum-starved). Then cells
were treated with ethanol (vehicle control, 0.01% final
volume), 10 nM E2 for each time course or pretreated
with 1 μM ICI 182, 780 or raloxifene respectively for 6 h,
then treated in combination with 10 nM E2 for 48 h.
Western blot
Cells were harvested and whole cell extracts were pre-
pared in modified RIPA buffer and separated by 4-12%
NuPAGE Bis-Tris gel electrophoresis (Invitrogen, Carls-
bad, CA). Proteins were transferred onto PVDF mem-
brane and probed with anti-cyclin D1, anti-bcl-2 (Santa
Cruz Biotechnology, Santa Cruz, CA), anti-survivin (R&D
systems, Minneapolis, MN) antibodies at 4°C overnight,
then the membrane was incubated with secondary anti-
body for 1 h before chemiluminescence detection using
Pierce ECL Western Blotting Substrate (Pierce, Rockford,
IL). b-actin was also detected as a loading control using
mouse monoclonal antibody (Sigma, St. Louis, MO).
Transfection of siRNA and miRNA
MiR-16, miR-143, miR-203 mimics and inhibitors were
purchased from Ambion and transfected into cells with
lipofectamine 2000 (Invitrogen, Carlsbad, CA). The final
concentration of miR-16, miR-143, miR-203 mimics and
inhibitors was 40 nM. After 48 h, cells were harvested
and bcl-2, cyclin D1 and survivin expression were mea-
sured. A nonspecific miRNA mimic or inhibitor was
used as negative control.
ERa siRNA was purchased from Dharmacon SMART-
pool siRNA, MCF-7 cells were transfected with 100 nM
ERa siRNA for 24 h using lipofectamine 2000, then sti-
mulated with 10 nM E2 for 24 h and 48 h.
Real-time quantitative PCR (QPCR)
For detection of miRNA expression, miScript Reverse
Transcription Kit (Qiagen, Valencia, CA) was used for
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cDNA synthesis. miScript SYBR Green PCR Kit (Qiagen,
Valencia, CA), in combination with a pair of miRNA
specific primers were used for mature miRNA detection.
RNU6B was used as an internal control. Taqman probes
and gene specific primers for FAM-labeled ERa and
VIC-labeled b-actin were obtained from Applied Biosys-
tem (Foster City, CA) and PCR condition for determina-
tion of ERa mRNA level was described previously [21].
Relative gene expression was determined using a pre-
viously described method [22].
Plasmid construction and luciferase assay
To make luciferase constructs containing 3’ UTR of sur-
vivin, 3’UTR was amplified using a pair of primers
whose sequences were 5’-gcTCTAGActgcctggtccca-
gagtg-3’and 5’-gcTCTAGAtaaaaccacatgagactttattgg-3’.
PCR was performed with genomic DNA and digested
using Xba I and ligated into pGL3-control vector (Pro-
mega Corporation, Madison, WI). The constructs were
sequenced to ascertain the right orientation and authen-
ticity in the vector. The 3’ UTR of bcl-2 and cyclin D1
cloned into Xba I site of pGL-3 promoter were kindly
provided by Dr. Ruggero De Maria (Mediterranean
Institute of Oncology, Catania, Italy).
Cells were plated in a 96-well plate and grown to 80-
90% confluence. The firefly luciferase constructs (100
ng) were cotransfected with 40 nM miRNA mimics into
MCF-7 cells using lipofectamine 2000 reagent. To moni-
tor transfection efficiency, cells were cotransfected with
10 ng of the pRL-SV40 plasmid which encodes Renilla
luciferase. Luminescence was measured 24 h after trans-
fection using a dual-luciferase reporter assay system
(Promega Corporation, Madison, WI). All transfections
were performed in triplicate, and data were analyzed by
normalizing firefly luciferase activity to Renilla luciferase
activity for each sample. Each construct was tested in
three independent transfections.
MTS Cell proliferation assay
MCF-7 cells were incubated in 5% charcoal stripped FBS
for 24 h, then transfected with 40 nM negative control
or miR-143, miR-16 and miR-203 mimics. After 24 h,
cells were trypsinized into 96-well plates. Cells were
treated with 10 nM E2 or ethanol (vehicle control) for 5
days, CellTiter 96 AQueous One Solution Cell Prolifera-
tion Assay (MTS) (Promega Corporation, Madison, WI)
was performed to detect cell proliferation.
Triple positive and negative breast cancer tissues
Fourteen triple positive and 36 triple negative formalin-
fixed paraffin-embedded (FFPE) breast cancer tissue spe-
cimens were obtained from Bioserve Global Bioreposi-
tory (Beltsville, MD). RNA was isolated from these FFPE
tissue specimens using miRNeasy FFPE kit (Qiagen,
Valencia, CA) for detection of miR-16, miR-143 and
miR-203 expression in triple positive and triple negative
breast samples. MiR-631, a non-estradiol inducible
miRNA was used as control. These studies were
approved by the Institutional Review Board at University
of Arkansas for Medical Sciences.
Statistical analysis
The differential analysis per miRNA expression was per-
formed using a 2-sample (treated vs. control and triple
positive vs. negative samples) Student’s t-test. Micro-
RNAs expression was normalized with respect to RNU6B
as an internal control. All statistical analyses were per-
formed using the SAS software (version 9.1; SAS Insti-
tute, Inc., Cary, NC). A P value of less than 0.05 (2-sided)
was considered to be statistically significant.
Results
Identification of estradiol induced cell proliferation and
survival genes in MCF-7 cells
ER-positive MCF-7 cells have been extensively used as a
model of hormone-dependent breast cancer. In response
to E2 stimulation, MCF-7 cells exhibit cell proliferation
and growth response in an E2 dependent manner. Bcl-2,
cyclin D1 and survivin have been shown to be implicated
in the process of cell proliferation and survival. In pre-
vious studies, bcl-2 [7,23,24] and cyclin D1[9,10,25]
mRNA levels have been found to be upregulated by E2.
Yet very few studies on the regulation of survivin by E2
[12]. Consistently, we found that E2 significantly induced
cyclin D1 expression at 6 h and 24 h, it also dramatically
enhanced bcl-2 and survivin expression at 24 h and 48 h
(Figure 1). The upregulation of bcl-2, cyclin D1 and sur-
vivin induced by E2 was in a time-dependent manner.
Downregulation of a panel of miRNAs induced by E2
ERa-mediated transcriptional regulation is one of the
mechanisms of gene upregulation induced by E2. MiR-
NAs have recently been shown to be another important
post-transcriptional regulation of genes involved in cell
growth and estradiol response in MCF-7 cells [18,26,27].
In order to explore whether miRNAs participate in the
upregulation of bcl-2, cyclin D1 and survivin induced by
E2, we focused on the downregulated miRNAs that could
play a role in the modulation of cell proliferation and sur-
vival genes at the post-transcriptional level. Based on pre-
vious miRNA array profilings [18,20], QPCR was
performed to examine the expression of miRNAs and it
showed that miR-143, miR-16 and miR-203 were
robustly repressed at 6, 24 and 48 h upon E2 treatment
(Figure 2) miR-631, a non-estradiol inducible miRNA,
was used as a control in response to E2 treatment.
T47D is another estrogen responsive ERa positive
breast cancer cell line which is used to examine the
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expression of bcl-2, cyclinD1 and survivin in response to
E2 treatment. Consistently, E2 enhanced the expression
of these genes but moderately reduced the expression of
miR-16, miR-143 and miR-203 as shown in Additional
file 1: Figure S1. Therefore, T47D cells displayed a simi-
lar effect in response to E2 stimulation, although the
effect was weaker than that of MCF-7 cells.
MiRNAs regulate bcl-2, cyclin D1 and survivin at the post-
transcriptional level
E2 treatment leads to an increase in cell proliferation
and survival genes bcl-2, cyclin D1 and survivin, it can
also reduce the expression of several miRNAs. So we
hypothesize that E2 upregulates target genes associated
with cell proliferation and survival by coordinately sup-
pressing the expression of miR-143, miR-16 and miR-
203. It has been clearly demonstrated that miR-15 and
miR-16 cluster targets bcl-2 and cyclin D1 [28,29] and
miR-143 targets bcl-2 [30]. Our results were in accor-
dance with previous studies as shown in Figure 3A and
3B. These miRNAs were able to significantly downre-
gulate endogenous target genes bcl-2 and cyclin D1
expression at the protein level. QPCR was used to
examine the level of the miRNAs and it indicated that
transfection of miRNA mimics remarkably increased
the level of miRNAs (Figure 3C). Furthermore, Tar-
getScan and miRbase programs predict conserved
binding sites of miR-16, miR-143 and miR-203 in the
3’-UTR of survivin. We further confirmed that these
miRNAs target survivin at the post-transcriptional
level by transfection of miRNA inhibitors and subse-
quent luciferase assay. It has been shown that transfec-
tion of miRNA inhibitors can potentially interfere with
the expression of endogenous miRNAs and therefore
enhance the expression of target gene survivin (Figure
3D and 3E).
Figure 1 E2 induced bcl-2, cyclin D1 and survivin expression in MCF-7 cells. (A) MCF-7 cells were incubated with phenol red-free IMEM
supplemented with 5% charcoal stripped FBS for 48 h (serum-starved). Then cells were treated with vehicle control or 10 nM E2 for 6, 24 and 48
h, total protein was extracted to detect the expression of bcl-2, cyclin D1 and survivin by Western blot. (B) The densitometry of each gene vs. b-
actin was indicated and the statistical analysis was shown. * denotes P < 0.05 compared with vehicle control.
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The biological activity of miRNAs is primarily
mediated by interaction with binding sites in the 3’-UTR
of target genes and translational inhibition. Finally, luci-
ferase assay was performed to confirm the binding of
the miRNAs to the 3’UTR of target genes. MCF-7 cells
were co-transfected with miR-16, miR-143 or miR-203
mimics with bcl-2, cyclin D1, survivin 3’-UTR luciferase
constructs containing the miRNAs binding sites respec-
tively. As expected, miR-16 significantly suppressed the
luciferase activity of bcl-2, cyclin D1, and survivin
whereas miR-143 moderately inhibited luciferase activity
of bcl-2 and survivin. Noticeably, miR-203 impaired
luciferase activity of survivin. Therefore, the luciferase
assay revealed that these miRNAs directly regulate the
expression of the target genes bcl-2, cyclin D1, and sur-
vivin by binding to the 3’UTR of these genes (Figure
3F). Based on our previous results, it is likely that E2-
mediated reduction in miRNAs expression resulted in
lower amounts of miRNAs available to bind to their
recognition sequences of bcl-2, cyclin D1 and survivin
and thus increasing the luciferase activity of the reporter
transcripts. This is possibly one mechanism of E2
induced upregulation of genes involved in cell
proliferation.
Regulation of miRNAs and the expression of target genes
are ERa-dependent
To investigate whether E2-mediated miRNA reduction
and upregulation of target genes can be abrogated by
anti-estrogens, we used ICI 182, 780 and raloxifene as
antagonists of E2. ICI 182, 780, a pure antiestrogen, is a
competitive antagonist of E2 and blocks the transcrip-
tional activation properties of ERs [31,32]. Raloxifene
belongs to the family of selective estrogen receptor
modulators (SERMs) that display agonistic or antagonis-
tic activity in a tissue-dependent manner [33]. As we
have shown, both ICI 182, 780 and raloxifene can
attenuate the reduction of the miRNAs and conse-
quently the induction of bcl-2, cyclin D1 and survivin
expression by E2 (Figure 4A, B).
E2 binds predominantly to ERa which leads to tran-
scriptional regulation of genes involved in the control of
cell growth and survival. To explore whether regulation
of miRNA and the target genes is ERa-dependent,
siRNA was used to interfere with the expression of ERa.
It was found that knockdown of ERa remarkably
impaired the induction of bcl-2, cyclin D1 and survivin
by E2 (Figure 4C, D). In addition, E2-regulated cell pro-
liferation and survival genes were examined in ER-nega-
tive MDA-MB-231 cells compared with those of MCF-7
cells. In contrast, E2 could not enhance bcl-2, cyclinD1
and survivin expression in MDA-MB-231 cells (Figure
4E). Further studies on miRNA expression indicated
that miR-16, miR-143 and miR-203 were not signifi-
cantly affected by E2 in MDA-MB-231 cells (Figure 4F),
indicating the potential modulation of cell growth and
survival genes by miRNAs in reponse to E2 was
mediated by ERa.
Figure 2 E2 reduced miR-16, miR-143 and miR-203 expression in MCF-7 cells. MCF-7 cells were treated as described in Figure 1 and
stimulated by E2 for 3, 6, 24 and 48 h. Total RNA was extracted and miRNA expression levels were examined by QPCR. MiR-631 is a non-E2
responsive miRNA serving as negative control. * denotes P < 0.05 compared with vehicle control.
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Figure 3 E2-responsive miRNAs downregulated endogenous bcl-2, cyclin D1 and survivin expression. (A) MCF-7 cells were transfected
with 40 nM miR-16, miR-143 and miR-203 mimics for 48 h, Western blot was performed to detect endogenous bcl-2, cyclin D1 and survivin
expression. (B) The densitometry of each gene vs. b-actin was indicated and statistically analyzed. * denotes P < 0.05 compared with negative
control miRNA. (C) RNA was extracted from MCF-7 transfected with miRNA mimics and RT-QPCR was performed to confirm the overexpression
of these miRNAs. (D, E) MCF-7 cells were transfected with 40 nM miR-16, miR-143 and miR-203 inhibitors. After 48 h, Western blot was
performed to examine endogenous survivin expression. Meanwhile, RT-QPCR was performed to examine the miRNAs expression. (F) MCF-7 cells
were co-transfected with 40 nM miR-16, miR-143 and miR-203 mimics together with 100 ng bcl-2, cyclin D1 and survivin 3’UTR luciferase
constructs and 10 ng pRL-SV40. After 24 h, luciferase activity assay was determined. * denotes P < 0.05 compared with negative control.
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MiR-16, miR-143 and miR-203 suppress E2-dependent cell
proliferation
E2 functions as a mitogen to stimulate cell proliferation
and cell cycle transition. In response to E2 treatment,
miR-143, miR-16 and miR-203 were repressed and their
target genes bcl-2, cyclinD1 and survivin were upregu-
lated. We therefore investigated whether overexpression
of miR-143, miR-16 and miR-203 interfered with E2-
induced cell proliferation in MCF-7 cells. The MTS
assay showed that transfection of miR-143, miR-16 and
miR-203 significantly inhibited E2-induced cell prolifera-
tion (Figure 5A). Since miRNAs regulated bcl-2, cyclin
D1 and survivin at the endogenous level as shown in
Figure 3A, we further explored whether transfection of
these miRNAs impaired E2-induced upregulation of bcl-
2, cyclin D1 and survivin that control cell proliferation
and cell cycle transition. As shown in Figure 5B and 5C,
Western blot and densitometry were performed to
determine the protein levels of these genes. In negative
control miRNA group, E2 significantly induced upregu-
lation of bcl-2, cyclin D1 and survivin compared with
vehicle control. Figure 5D depicted the statistical analy-
sis of the gene expression based on the results from Fig-
ure 5C. The miRNAs significantly inhibited E2-induced
cyclin D1 upregulation, in particular miR-16 inhibited
E2 induced upregulation of cyclin D1 by 41% compared
Figure 4 Regulation of miRNAs and the expression of target genes are ERa-dependent. (A, B) MCF-7 cells were pretreated with 1 μM ICI
182, 780 or Raloxifene for 6 h, then treated with 10 nM E2 for 48 h, protein was used for detection of bcl-2, cyclinD1 and survivin expression by
Western blot. RNA was used to detect the expression of miRNAs by QPCR. * denotes P < 0.05 compared with vehicle control (ethanol). (C, D)
MCF-7 cells were transfected with 100 nM ERa siRNA for 24 h, then cells were treated with 10 nM E2 for 24 h and 48 h. Western blot was used
to detect the expression of bcl-2, cyclin D1 and survivin. QPCR was used to examine the level of ERa mRNA. (E, F) MDA-MB-231 cells were
treated with 10 nM E2 for 24 and 48 h, miRNAs and target genes were examined. MCF-7 cells were used as ER-positive control.
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with negative control miRNA group. But the miRNAs
have little inhibitory effects on E2-induced bcl-2 and no
inhibitory effects on E2-induced survivin at all when
compared with negative control miRNA group (Figure
5D). This probably was due to the robust interference of
endogenous genes by the miRNAs in each group, which
was in agreement with the result of Figure 3A. More
importantly, these miRNAs impaired E2-induced gene
upregulation when compared with E2-induced negative
control miRNA group. The data indicated that miR-143,
miR-16 and miR-203 not only inhibited endogenous
expression of bcl-2, cyclinD1 and survivin, but also dis-
turbed E2-induced upregulation of cyclin D1, an
important cell cycle regulator, thereby, accounting for
the impairment of cell proliferation.,
MiR-16, miR-143 and miR-203 are highly expressed in ER
positive breast tumors
Triple-negative and triple positive breast cancers are
defined by the status of estrogen receptor (ER), proges-
terone receptor (PR) and HER-2 expression. Because the
triple-negative phenotype is more aggressive and not
amenable to any form of endocrine therapy and has a
high incidence of metastasis, the patients have a worse
prognosis than patients with the triple positive pheno-
type [8]. Since miR-16, miR-143 and miR-203 target
Figure 5 MiRNAs inhibit E2-induced cell proliferation. MCF-7 cells were transfected with 40 nM miR-16, miR-143 and miR-203 and treated
with 10 nM E2 for 5 days. (A) MTS assay was used to detect cell proliferation. * denotes P < 0.05 compared with vehicle control. (B) MCF-7 cells
were transfected with 40 nM miR-16, miR-143 and miR-203 and treated with 10 nM E2 for 48 h. Western blot was used to detect bcl-2, cyclin D1
and survivin expression. (C) The densitometry of each gene vs. b-actin was indicated. In negative control miRNA group, E2 significantly induced
upregulation of bcl-2, cyclin D1 and survivin compared with vehicle control (* denotes P < 0.05). (D) In each miRNA-transfected group, the
expression of bcl-2, cyclin D1 and survivin induced by E2 was normalized by that of vehicle control (ethanol). The fold change was statistically
analyzed compared with negative control miRNA group. * denotes P < 0.05 compared with control.
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genes control cell proliferation and the miRNAs exhibit
a growth suppressive effect in response to E2, we specu-
lated that these miRNAs may be differentially expressed
in ER positive and negative breast tumors, acting as a
potential causal link with tumor suppressive effects in
breast cancer progression. Notably, as shown in Figure
6, miR-16, miR-143 and miR-203 were highly expressed
in ER positive breast tumor, in contrast, miR-631 was
not differentially expressed between ER positive and
negative breast cancer, suggesting these anti-onco miR-
NAs may play an important role in breast cancer pro-
gression and response to chemotherapy.
Discussion
The discovery of miRNAs as a novel class of gene
expression regulators has provided new strategies for
disease diagnostics and therapeutics. Cell cycle, cell pro-
liferation, cell survival and tumorigenesis are all regu-
lated by miRNAs. Altered abundance of cell survival
and cell cycle regulation proteins and aberrant expres-
sion of miRNAs frequently coexist in human breast can-
cers [34]. miRNAs are aberrantly expressed or mutated
in cancer, acting as a novel class of oncogenes or tumor
suppressor genes [35]. In this study, we demonstrated
that a set of E2-repressible microRNAs in breast cancer
cell lines was associated with altered cell cycle progres-
sion and cell proliferation, which could play a causal
role for miRNAs in controlling breast tumor growth.
In breast cancer, abnormalities of the cell cycle are
frequently observed in response to E2 treatment. Cyclin
D1 encodes a key regulator of the cell cycle transition
from G1 to S phase and is overexpressed in more than
50% of breast cancers, functioning as a rate-limiting fac-
tor for human breast cancer cell proliferation in vivo
and in vitro [36,37]. The bcl-2 protein is associated with
the inner mitochondrial membrane and functions to
inhibit apoptosis and promote survival [38,39]. Survivin,
a member of the inhibitor of apoptosis (IAP) family of
antiapoptotic proteins, regulates the G1 checkpoint and
G2/M phase of the cell cycle by associating with mitotic
spindle microtubules. Survivin directly inhibits caspase-3
and caspase-7 activity, is inversely correlated with apop-
tosis and is positively correlated with cell proliferation
[40,41]. We demonstrated that E2 induced upregulation
of cyclin D1, bcl-2 and survivin in MCF-7 cells, which
played an important role in E2 stimulated cell prolifera-
tion and cell cycle transition. This result was consistent
with previous studies [7,9,10,23-25]. Similar results were
also observed in another estrogen-responsive breast can-
cer cells T47D, E2 dramatically induced the expression
of cyclin D1, bcl-2 and survivin as shown in Additional
file 1: Figure S1.
MiRNAs have emerged as a novel regulator of gene
expression at the post-transcriptional level by base-
pairing interactions between miRNAs and the 3’-UTR of
their target mRNAs [16]. In order to explore whether
miRNAs participate in the upregulation of bcl-2, cyclin
D1 and survivin by E2, we focused on the E2-repressible
miRNAs that may play a role in the modulation of cell
proliferation and survival genes. Several studies have
demonstrated that E2 upregulates or downregulates a
variety of miRNAs by miRNA expression profilings in
MCF-7 cells [18-20]. The difference of the results may
be due to the cell status, treatment and stimulation
time. Based on previous studies, we demonstrated miR-
16, miR-143 and miR-203 were coordinately suppressed
in response to E2 treatment using QPCR quantification.
Therefore, we proposed that these miRNAs might be
involved in the regulation of cell proliferation and survi-
val by targeting bcl-2, cyclin D1 and survivin at the
post-transcriptional level.
Some publications have provided support for our
hypothesis, Cimmino et al. [28] have demonstrated that
miR-15a and miR-16 expression is inversely correlated
with bcl-2 expression in Chronic lymphocytic leukemia
and that both microRNAs negatively regulate bcl-2 at a
post-transcriptional level. Bonci et al. [29] have demon-
strated that the miR-15a-miR-16 cluster targets CCND1
(encoding cyclin D1), acting as tumor suppressor genes
in prostate cancer by the control of cell survival, prolif-
eration and invasion. miR-143 has been validated to tar-
get the oncogene KRAS [42] and may also modulate
extracellular-regulated protein kinase 5 (ERK5) [43,44]
and bcl-2 [30]. In this study, we confirmed the previous
studies that miR-16 targets bcl-2 and cyclin D1 and
miR-143 targets bcl-2. However, we can also see the
impairment of endogenous cyclin D1 by miR-143 as
shown in Figure 3A, which may result from the interfer-
ence of ERK5 expression by miR-143 [30], since ERK5
has been shown to regulate cyclin D1[45,46]. TargetScan
and miRbase programs predict conserved binding sites
of miR-16, miR-143 and miR-203 in 3’-UTR of survivin.
We further elucidated that miR-16, miR-143 and miR-
203 target survivin at the post-transcriptional level by
transfection of miRNA mimics and inhibitors. Luciferase
activity assay indicated these miRNA directly regulated
the expression of survivin by binding to the 3’-UTR of
survivin.
A miRNA regulates a variety of target genes, and a
gene is modulated by many miRNAs. Therefore, in
response to E2 stimulation, several miRNAs are coordi-
nately suppressed to upregulate the target genes which
are involved in cell proliferation and survival. It provides
a novel mechanism for regulation of genes containing
ERE in the promoters. Previous studies have shown the
ERa-mediated transcriptional regulation of bcl-2, cyclin
D1 mRNAs by binding to the ERE of target genes. We
cannot conclude that the increase of bcl-2, cyclin D1
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and survivin is due solely to E2-mediated reduction of
miR-16, miR-143 and miR-203, but miRNAs do play a
crucial role in the post-transcriptional regulation
because when actinomycin D was used to inhibit de
novo RNA synthesis, E2 can still enhance the expression
of bcl-2, cyclinD1 and survivin, though at a low level
(Additional file 2: Figure S2). Further studies will be
needed to dissect the relative contributions of ERa-
mediated multiple pathways controlling bcl-2, cyclin D1
and survivin expression.
Figure 6 miRNAs were highly expressed in triple positive breast cancer tissues. (A-D) Total RNA was extracted from 14 triple negative and
36 triple positive breast cancer tissues to detect miRNAs expression by QPCR. MicroRNAs expression was normalized with respect to RNU6B as
an internal control. T-test was used to indicate the difference. P values are shown in the figures. TP denotes triple positive breast samples, TN
means triple negative breast samples.
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ERa is essential for E2-dependent growth, and its level
of expression is a crucial determinant of response to
endocrine therapy and prognosis in ERa-positive breast
cancer. Our data indicated that ICI 182, 780 and Raloxi-
fene can abrogate E2 repressed miRNA levels and there-
fore attenuate the expression of target genes. It is
reported that ICI 182, 780 and Raloxifene can locally
alter the ERa ligand binding structure via specific
hydrophobic residues and decrease its transcriptional
activity [47]. In addition, knockdown of the ERa protein
also impaired E2 induced upregulation of bcl-2, cyclin
D1 and survivin. In ERa negative MDA-MB-231 cells,
E2 has no effect on the regulation of miRNAs and target
genes as shown in Figure 4E and 4F. In ERa negative
non-cancer cells MCF-10A, we also observed similar
effect (data not shown). Thus, the regulation is mainly
dependent on ERa protein expression and transactiva-
tion in both breast cancer cells and in a normal breast
cells.
Suzuki et al. [48] have recently shown that a central
tumor suppressor, p53, enhances the post-transcrip-
tional maturation of several miRNAs with growth-sup-
pressive function, including miR-16, miR-143, miR-145
and miR-203 in response to DNA damage. P53 interacts
with the Drosha processing complex through the asso-
ciation with the DEAD-box RNA helicase p68 and facili-
tates the processing of primary miRNAs to precursor
miRNAs. In our study, we used MCF-7 cells carrying
wild type p53 genes as a model to investigate the E2-
repressible miRNAs target genes involved in cell prolif-
eration. However, in p53 mutant ERa-positive T47D
cells, we observed similar regulation yet to a weaker
extent. Previous studies have elucidated the interaction
of ERa and p53 [49,50]. It is likely that both ERa and
p53 participated in the regulation of E2-repressible miR-
NAs. Further studies are needed to elucidate whether
ERa-mediated induction of target genes by E2 via p53-
regulated miRNA maturation.
The downregulated miRNA exhibits the growth sup-
pressive effect in response to E2. miR-16 and miR-15 act
as tumor suppressors and control cell cycle transition by
targeting cyclin D1 and cyclin E [29,51]. MiR-143 has
been claimed to be a anti-oncomir in human colorectal
tumors and can increase the sensitivity of chemotherapy
[30,52-54]. MiR-203 has recently been identified to inhi-
bit cell proliferation and invasion in prostate cancer,
and reverse chemoresistance in p53-mutated colon cells
[55-57]. In this study, overexpression of miR-16, miR-
143 and miR-203 remarkably inhibited E2 induced cell
proliferation of breast cancer cells. Further studies have
shown that these miRNAs were significantly higher in
triple positive than in triple negative breast tissues. This
suggested a potentially tumor suppressive effect of the
miRNAs on cancer progression of ER positive breast
cancers, which may open new avenues for therapeutic
intervention in breast cancer treatment.
Conclusions
It is our novel discovery that estradiol suppressed a
panel of miRNAs, involving in the coordinated modula-
tion of target genes that control cell proliferation and
survival in breast cancer progression. Importantly, these
miRNAs manifest tumor suppressive effects in response
to estradiol stimulation and could possibly be biomar-
kers in triple positive breast tumors. In addition they
may be potential biomarkers of breast cancer subtypes.
Uncovering the critical role of these miRNAs in tumor
suppression will contribute to the efficacy of breast can-
cer therapy.
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